Navigation Links
Popular Diabetes Drug Might Cut Pancreatic Cancer Risk: Study
Date:1/31/2012

By Alan Mozes
HealthDay Reporter

TUESDAY, Jan. 31 (HealthDay News) -- A new Swiss-American study indicates that long-term use of the popular diabetes medication metformin may lower the risk of developing pancreatic cancer, at least among women.

The researchers also found that the long-term use of another class of diabetes medications known as sulfonylureas was associated with a "substantial" bump in pancreatic risk and long-term insulin use was linked to a bump in pancreatic cancer risk in men.

"This result is somewhat unexpected," the team wrote in its paper, which is published in the Jan. 31 online issue of The American Journal of Gastroenterology.

Pancreatic cancer is the fourth most deadly cancer in the United States, with an overall survival rate of less than 5 percent, even though it is fairly rare, according to the U.S. National Institutes of Health.

The researchers noted that previous research has suggested that metformin may lower the risk for other cancers, breast and ovarian cancer in particular.

To explore metformin's protective potential against pancreatic cancer, the team sifted through drug prescription, diagnostic, hospitalization and fatality information that had been collected by the British "General Practice Research Database." The data also included significant demographic information, such as smoking, alcohol use and body mass index.

The team honed in on statistics regarding nearly 2,800 patients (all under the age of 90) who had been diagnosed with pancreatic cancer for the first time between 1995 and 2009. Data concerning almost 16,600 patients who did not have pancreatic cancer was used as a comparison.

The result: Short-term use of metformin or sulfonylureas and/or insulin had no appreciable impact on pancreatic cancer risk.

However, long-term use of each of these medications did appear to have a sizeable impact on pancreatic cancer risk among diabetics. While female patients saw their risk go down with metformin treatment and up with sulfonylureas, male patients saw their risk go up with insulin.

Dr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, stressed the "importance of trying to identify causes for a devastating disease that is often diagnosed late."

"Over the years, many groups have tried to look at a variety of risk factors, dietary and other things, and there have been some reports over the years," he noted. "But nothing has really panned out well. So this is indeed an interesting study."

"But it's also important to say," Choti added, "that while these could be associations, we cannot really say that what we have here is a cause-and-effect. Pancreatic cancer is a multi-factorial disease. So, while it makes sense conceptually that these drugs could have an impact on the pancreas, which is a metabolic organ, it's still too early to be sure what's happening. And it's too early to recommend metformin as a preventive therapy for pancreatic cancer."

"So this is interesting and important," he said. "But it's not definitive."

More information

For more on pancreatic cancer, visit the U.S. National Library of Medicine.

SOURCES: Michael Choti, M.D., professor, surgery and oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore; Jan. 31, 2012, The American Journal of Gastroenterology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Is a Tummy Tuck Right for Me? Alabama Plastic Surgeon Dr. David Durst Offers Tips as the Popularity of Surgical Cosmetic Enhancement Continues to Rise
2. Americans Remain Split on Stalled Health Care Legislation, but Some Provisions Popular Among Majorities of Democrats, Independents and Republicans
3. Popular Diet Plans Can Unclog Arteries
4. Popular nanoparticle causes toxicity in fish, study shows
5. Personalized Live on-Demand Yoga Avatar Gains Popularity Amongst Users, Across all age Groups
6. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
7. "How Stupid Do They Think We Are?" --- Band Releases New Anthem in Support of Popular Citizens' Resistance
8. Future Apps Releases Major Update to its Popular iPhone Text to Speech App Speak it
9. Electronic Cigarettes Continue to Experience Popularity Growth
10. Passover paradox: The amazing popularity of kosher foods
11. Quantity, Not Quality, of Online Posts Builds Popularity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Popular Diabetes Drug Might Cut Pancreatic Cancer Risk: Study
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart ... in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is ... for a brain tumor. , Jason Bauer and his family are longtime members ...
(Date:12/7/2016)... ... , ... A. Kevin Spann Insurance, a New York-based firm offering insurance and ... a charity drive to raise funds that will benefit the Marine Corps League. , ... Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and ... The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® Products Now ... the Phoenix Valley with Delightful Deals on Botox® and Juvederm® just in ...
(Date:12/7/2016)... CINCINNATI, Ohio (PRWEB) , ... December 07, 2016 ... ... winner in the 2016 BOC Business Brilliance Awards under the Best New Product ... inception and results achieved through user experience. , BOC Global Events & Training ...
(Date:12/7/2016)... , ... December 07, 2016 , ... “Walking With God: ... stories that will inspire the reader to be aware of God's direction in their ... published author, Sanford Smith, retired teacher and active church leader. , Sanford ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... NESS ZIONA SCIENCE PARK , ... Israeli biotechnology company Kadimastem (TASE: KDST) announced today the signing of ... strategic collaboration between the companies. The synergy between the companies will ... Kadimastem-Corestem collaboration as a worldwide leader in innovative treatment for severe ... ...
(Date:12/7/2016)... December 7, 2016 According to a new market ... Mode, Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity ... Market is expected to reach USD 1,519.2 Million by 2021 from USD ... Continue Reading ... ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
Breaking Medicine Technology: